A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Recruiting now · Phase 2
Conditions studied: Recurrent Glioblastoma
In brief
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.
Key facts
- Study ID
- NCT07297212
- Run by
- BioNTech SE
- People needed
- 75
- Starts
- 2026-01-15
- Expected to finish
- 2029-07-01
- Last updated by the study team
- 2026-04-29
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beijing Tiantan Hospital, Capital Medical University — Beijing, China (enrolling)
- Affiliated Tumor Hospital of Chongqing Medical University — Chongqing, China (enrolling)
- Affiliated Cancer Hospital of Shandong First Medical University — Jinan, China (enrolling)
- Huashan Hospital, Fudan University — Shanghai, China (enrolling)
- Shenzhen Second People's Hospital — Shenzhen, China (enrolling)
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.